The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. Cooperative Multicenter EPO Clinical Trial Group.
The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. Cooperative Multicenter EPO Clinical Trial Group.
复制标题
用重组人促红细胞生成素治疗的血液透析接受者的生活质量。
DOI：
--
复制
发表时间：
1990
期刊：
影响因子：
--
通讯作者：
D. Manninen
中科院分区：
文献类型：
--
作者：
R. Evans;B. Rader;D. Manninen
重组人促红细胞生成素的初步临床试验为接受维持性血液透析的贫血终末期肾病患者提供了生活质量改善的证据。作为重组人促红细胞生成素第三阶段临床试验的一部分，系统地评估了患者的生活质量。对9个透析中心的300多名患者进行了评估。在基线和第二次随访之间，大多数客观和主观生活质量参数得到了显著改善，包括能量和活动水平、功能能力、睡眠和饮食行为、疾病症状、健康状况、健康满意度、性生活、幸福感、心理影响、生活满意度和幸福感。在工作能力或就业状况方面没有观察到变化。我们的结论是，除了血液学参数的显著改善外，重组人促红细胞生成素还极大地提高了接受维持性血液透析的贫血患者的生活质量。
Initial clinical trials with recombinant human erythropoietin provided evidence of a quality-of-life benefit for patients with anemic end-stage renal disease who received maintenance hemodialysis. As part of a phase III clinical trial of recombinant human erythropoietin, the quality of life of patients was systematically assessed. More than 300 patients at nine dialysis centers were evaluated. A statistically significant improvement was established between baseline and second follow-up on most objective and subjective quality-of-life parameters, including energy and activity level, functional ability, sleep and eating behavior, disease symptoms, health status, satisfaction with health, sex life, well-being, psychological affect, life satisfaction, and happiness. No change was observed in ability to work or employment status. We conclude that, in addition to substantial improvement in hematologic parameters, recombinant human erythropoietin greatly enhances the quality of life of anemic patients who receive maintenance hemodialysis.